Capsugel Enters Agreement with Chiasma to Manufacture Oral Octreotide Acetate
PTSM: Pharmaceutical Technology Sourcing and Management
Capsugel enters an agreement with Chiasma to increase manufacturing operations for octreotide, a treatment for acromegaly.
Capsugel reported an agreement with Chiasma, in which Capsugel’s Dosage Form Solutions (DFS) business unit will increase manufacturing operations for the only investigational oral form of octreotide in clinical development. The drug candidate is in Phase 3 clinical trials for the treatment of acromegaly, a disorder that develops when a person's pituitary gland produces too much growth hormone. This agreement extends the companies’ existing product-development relationship.
Scale-up activities for the drug are underway at Capsugel’s site in Livingston, Scotland. Capsugel DFS has already manufactured several clinical batches of the compound, including those needed for the new drug application (NDA) registration. Commercial scale batches are expected to be validated during Q4 2014/Q1 2015.
Octreotide acetate is the lead candidate for Chiasma, a privately owned biopharmaceutical company that develops oral drugs previously only available by injection using its proprietary Transient Permeability Enhancer (TPE) System. Chiasma and Roche will develop and commercialize theproduct. If approved, oral octreotide acetate will offer the first oral alternative for the treatment of acromegaly.
Source: Capsugel
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
